Latest Period
Q2 2026
Security Snapshot
Enliven Therapeutics, Inc. - COMMON STOCK (ELVN) Institutional Ownership
CUSIP: 29337E102
13F Institutional Holders and Ownership History from Q1 2023 to Q2 2026
Institutions Reporting
212
Shares (Excl. Options)
80,193,639
Price
$50.75
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- ELVN on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 80,193,639
- Total 13F value
- $4,059,546,795
- Portfolio coverage rank
- 0.01%
- Share change
- +17,047,092
- Value change
- +$879,994,908
- Number of holders
- 212
- Shares outstanding
- 71,423,603
- SEC-reported price per share
- $59.42
- Insider filing price
- $59.42
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ELVN - Enliven Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 29337E102.
- 212 institutions reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 168 to 212 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $2,415,321,021 to $4,059,546,795.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 212 institutions filings for Q2 2026.
Security key
29337E102
Latest holder period
Q2 2026
13F holders
212
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
ELVN full holder history
Enliven Therapeutics, Inc. SEC filings
Enliven Therapeutics, Inc. company facts
Enliven Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29337E102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
ELVN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +13% | $544,997,801 | +$144,639,739 | 10,713,540 | +36% | FMR LLC | 30 Jun 2026 |
| ORBIMED ADVISORS LLC | 9.5% | -13% | $268,473,712 | -$34,086,674 | 6,774,507 | -11% | ORBIMED ADVISORS LLC | 22 Jun 2026 |
| Polar Capital Holdings Plc | 8.5% | +66% | $200,401,261 | +$99,864,667 | 5,056,807 | +99% | Polar Capital Holdings Plc | 31 Mar 2026 |
| Commodore Capital LP | 7.7% | -22% | $217,578,601 | -$55,381,810 | 4,800,940 | -20% | Commodore Capital LP | 31 Mar 2026 |
| Vestal Point Capital, LP | 5.4% | -16% | $147,290,000 | -$26,285,600 | 3,250,000 | -15% | Vestal Point Capital, LP | 31 Mar 2026 |
| BlackRock, Inc. | 5.1% | $59,005,266 | 2,941,395 | BlackRock, Inc. | 30 Jun 2025 | |||
| Fairmount Funds Management LLC | 3.1% | -53% | $84,097,786 | -$84,104,856 | 1,855,644 | -50% | Fairmount Funds Management LLC | 31 Mar 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 2.8% | -52% | $78,237,321 | -$67,980,000 | 1,726,331 | -46% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2026 |
As of 30 Jun 2026, 212 institutional investors reported holding 80,193,639 shares of Enliven Therapeutics, Inc. - COMMON STOCK (ELVN). This represents 112% of the company’s total 71,423,603 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
85%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 14% | 10,025,017 | +47% | 0.02% | $508,769,634 |
| ORBIMED ADVISORS LLC | 9.5% | 6,776,632 | -15% | 6.5% | $343,914,074 |
| Polar Capital Holdings Plc | 9% | 6,430,636 | +27% | 0.92% | $326,354,777 |
| BlackRock, Inc. | 6.1% | 4,359,704 | +18% | 0% | $221,254,979 |
| Vestal Point Capital, LP | 5.6% | 4,000,000 | +23% | 4.7% | $203,000,000 |
| Commodore Capital LP | 4.6% | 3,275,000 | 0% | 9.9% | $166,206,250 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.1% | 2,903,907 | +2871% | 0.01% | $147,374,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 2,569,002 | +18% | 0% | $130,376,852 |
| CITADEL ADVISORS LLC | 2.9% | 2,068,992 | +19% | 0.06% | $105,001,345 |
| Fairmount Funds Management LLC | 2.6% | 1,855,644 | 0% | 6.2% | $94,173,933 |
| Siren, L.L.C. | 2.5% | 1,774,411 | +138% | 1.8% | $90,051,358 |
| Bellevue Group AG | 2.1% | 1,490,000 | -36% | 1.6% | $75,617,500 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,407,202 | +32% | 0% | $71,430,882 |
| First Light Asset Management, LLC | 1.9% | 1,360,750 | +574% | 4.2% | $69,058,063 |
| STATE STREET CORP | 1.7% | 1,213,616 | +11% | 0% | $61,591,012 |
| Pictet Asset Management Holding SA | 1.6% | 1,161,784 | +25% | 0.06% | $58,960,538 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.5% | 1,083,313 | 0.08% | $54,978,135 | |
| NOVO HOLDINGS A/S | 1.4% | 1,000,000 | -22% | 3% | $50,750,000 |
| First Turn Management, LLC | 1.3% | 954,360 | +53% | 5.2% | $48,433,770 |
| SAMLYN CAPITAL, LLC | 1.3% | 912,637 | 0.77% | $46,316,328 | |
| Candriam S.C.A. | 1.3% | 905,674 | +52% | 0.21% | $45,918,733 |
| BAKER BROS. ADVISORS LP | 1.3% | 905,191 | 0% | 0.23% | $45,938,443 |
| ALLIANCEBERNSTEIN L.P. | 1.3% | 896,161 | 0% | 0.01% | $35,129,511 |
| Tri Locum Partners LP | 1.2% | 866,716 | 5.4% | $43,985,837 | |
| DIMENSIONAL FUND ADVISORS LP | 0.94% | 671,412 | -1.5% | 0.01% | $34,074,507 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
14
Latest
Q2 2026
Rows shown
1-14 of 14
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 80,193,639 | $4,059,546,795 | +$879,994,908 | $50.75 | 212 |
| 2026 Q1 | 61,617,761 | $2,415,321,021 | +$69,950,617 | $39.20 | 168 |
| 2025 Q4 | 62,391,024 | $960,824,930 | +$20,216,707 | $15.40 | 125 |
| 2025 Q3 | 59,389,507 | $1,215,687,864 | -$296,366 | $20.47 | 132 |
| 2025 Q2 | 59,434,902 | $1,192,251,085 | +$192,194,924 | $20.06 | 123 |
| 2025 Q1 | 49,886,849 | $983,923,667 | +$4,352,699 | $19.68 | 118 |
| 2024 Q4 | 49,624,914 | $1,116,597,658 | +$24,828,957 | $22.50 | 111 |
| 2024 Q3 | 47,688,348 | $1,218,010,157 | -$20,810,259 | $25.54 | 100 |
| 2024 Q2 | 48,318,843 | $1,129,194,355 | +$91,652,714 | $23.37 | 91 |
| 2024 Q1 | 44,456,336 | $780,753,492 | +$95,045,035 | $17.59 | 72 |
| 2023 Q4 | 39,000,634 | $539,791,932 | -$652,659 | $13.84 | 61 |
| 2023 Q3 | 39,076,502 | $533,779,750 | -$2,178,662 | $13.66 | 60 |
| 2023 Q2 | 39,092,843 | $797,915,923 | +$112,876,379 | $20.41 | 61 |
| 2023 Q1 | 33,557,749 | $734,910,999 | +$734,911,000 | $21.90 | 44 |